Introduction Craniofacial hyperhidrosis is a disabling condition, likely caused by an overactive neural pathway. We describe clinical characteristics and response to Botulinum toxin A injections.
Method 17 patients with craniofacial hyperhidrosis were prospectively studied. Exclusion criteria included sweating secondary to autonomic disease or unilateral/localized/gustatory sweating secondary to diabetes or Frey Syndrome.
Results Three groups emerged:
1. Familial early onset, childhood to puberty, n=8 88% also suffered hyperhidrosis at axillae/palmar-plantar/back areas. 75% had positive family history. Males : females=1 : 1. Triggers included anxiety, heat and physical exertion.
2. Adult onset, 27–30 years, n=5 60% had isolated facial sweating. 80% had negative family history. Males : females=4 : 1. 100% had psychiatric comorbidity. Citalopram triggered sweating in one case.
3. Late adult onset, 50–65 years, n=4 100% had negative family history. Males : females=1 : 1. Systemic comorbidities were lupus, acromegaly, polymyalgia rheumatica. Sweating worsened at night and was unaffected by emotion.
Botulinum toxin A injections were well-tolerated with no significant side-effects and duration 4–12 months. Injection techniques will be demonstrated via video.
Conclusion Craniofacial sweating is a heterogeneous disorder. Three distinct groups are apparent. Botulinum toxin A injections are effective and well-tolerated.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.